GO:0042377 vitamin K catabolic process: Metabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042377 vitamin K catabolic process describes the biochemical breakdown of vitamin K forms, including phylloquinone (vitamin K1) and menaquinones (vitamin K2).
• Vitamin K catabolism is essential for maintaining vitamin K homeostasis and preventing excessive accumulation of quinone-derived vitamins.
• The process involves oxidation, reduction, and conjugation reactions that convert vitamin K into more water-soluble metabolites for excretion.
• Key enzymes implicated in vitamin K catabolism include cytochrome P450 family members, NAD(P)H:quinone oxidoreductase 1 (NQO1), and UDP-glucuronosyltransferases (UGTs).
• Dysregulation of vitamin K catabolism has been linked to coagulation disorders, bone health, and cardiovascular calcification.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect the genetic regulation of vitamin K catabolic enzymes.
Description
Vitamin K refers to a group of fat-soluble vitamins that are essential for the post-translational gamma-carboxylation of blood clotting factors and other proteins. The term GO:0042377 vitamin K catabolic process encompasses the chemical reactions and pathways that result in the breakdown of any form of vitamin K, including phylloquinone (vitamin K1) and menaquinones (vitamin K2). This catabolic process is critical for regulating vitamin K levels in the body, as excessive accumulation can lead to toxicity, while insufficient catabolism may disrupt the balance of vitamin K-dependent processes. Research into vitamin K catabolism has gained attention due to its implications in coagulation, bone metabolism, and vascular health. The breakdown of vitamin K involves a series of enzymatic modifications, primarily in the liver, that convert the quinone ring into more polar metabolites for excretion. Understanding the genetic and biochemical basis of this process is essential for developing therapeutic strategies for disorders related to vitamin K imbalance. This article provides a comprehensive overview of GO:0042377, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and modern research methods including CRISPR-based models. All information is grounded in authoritative QuickGO data and verified PubMed literature [1-8].
vitamin K catabolic process At A Glance
| GO ID | GO:0042377 |
|---|---|
| GO term | vitamin K catabolic process |
| Ontology | biological_process |
| Synonym | naphthoquinone catabolic process; naphthoquinone catabolism; vitamin K breakdown; vitamin K catabolism; vitamin K degradation |
| Major function | Breakdown of vitamin K forms to maintain homeostasis and prevent toxicity |
| Substrates | Phylloquinone (vitamin K1), menaquinones (vitamin K2) |
| Location | Primarily liver, but also in other tissues |
| Key enzymes | Cytochrome P450, NQO1, UGTs |
| Related pathways | Vitamin K cycle, coagulation cascade, bone metabolism |
What Is GO:0042377?
GO:0042377 vitamin K catabolic process is defined as the chemical reactions and pathways resulting in the breakdown of any of the forms of vitamin K, which are quinone-derived vitamins involved in the synthesis of blood-clotting factors in mammals. This process includes the degradation of phylloquinone (vitamin K1) and menaquinones (vitamin K2) into metabolites that can be excreted from the body.
Why Is vitamin K catabolic process Important in Cell Biology?
The vitamin K catabolic process is crucial for maintaining physiological levels of vitamin K and preventing the accumulation of potentially toxic quinone metabolites. It ensures a proper balance between vitamin K intake, recycling, and excretion, which is vital for blood coagulation, bone health, and cardiovascular function. Dysregulation of this process can contribute to diseases such as vitamin K deficiency bleeding, osteoporosis, and vascular calcification.
• Maintains vitamin K homeostasis by eliminating excess vitamin K.
• Prevents toxicity from quinone-derived vitamins.
• Regulates availability of vitamin K for gamma-carboxylation of clotting factors.
• Impacts bone health through modulation of osteocalcin carboxylation.
• Influences cardiovascular health by affecting matrix Gla protein.
• Provides targets for therapeutic intervention in coagulation disorders.
• Plays a role in drug metabolism and detoxification pathways.
• Serves as a model for studying quinone catabolism in general.
• Relevant to nutritional science and vitamin K supplementation.
• Potential link to cancer biology via quinone metabolism.
What Happens During vitamin K catabolic process?
Initial Oxidation and Reduction Reactions
In simple terms: Vitamin K is first chemically modified by oxidation or reduction to make it more reactive.
The catabolism of vitamin K begins with redox reactions that alter the quinone ring. NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyzes the two-electron reduction of vitamin K to hydroquinone, which can then undergo further modifications. Cytochrome P450 enzymes may also oxidize the side chain or ring structure, introducing hydroxyl groups that facilitate subsequent conjugation.
Side Chain Shortening and Ring Modification
In simple terms: The long side chain of vitamin K is trimmed down, and the ring is modified to make it easier to excrete.
Following initial redox changes, the phytyl side chain of vitamin K1 or the prenyl side chain of menaquinones undergoes oxidative cleavage, likely mediated by peroxisomal or mitochondrial beta-oxidation-like mechanisms. The quinone ring may be further hydroxylated or demethylated, generating intermediates such as 2,3-epoxyvitamin K and other polar derivatives.
Conjugation Reactions
In simple terms: The modified vitamin K is attached to molecules like glucuronic acid to make it water-soluble.
The hydroxylated and shortened metabolites undergo conjugation with glucuronic acid, sulfate, or glutathione. UDP-glucuronosyltransferases (UGTs) are key enzymes that catalyze glucuronidation, converting vitamin K metabolites into water-soluble forms that can be excreted in bile or urine. Sulfotransferases may also contribute to the conjugation process.
Excretion of Metabolites
In simple terms: The final water-soluble products are removed from the body through urine or bile.
Conjugated vitamin K metabolites are transported to the kidneys or liver for excretion. The majority of vitamin K catabolites are excreted in bile as glucuronides, while a smaller fraction is eliminated via urine. This excretion completes the catabolic process and helps maintain vitamin K balance.
Key Genes Involved in GO:0042377 vitamin K catabolic process
The following genes encode enzymes and proteins directly involved in or regulating the vitamin K catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NQO1 | Reduces vitamin K to hydroquinone, initiating catabolism | Target for studying redox regulation of vitamin K |
| CYP4F2 | Oxidizes vitamin K side chain, facilitating breakdown | Genetic variants linked to vitamin K levels and anticoagulant response |
| UGT1A1 | Glucuronidates vitamin K metabolites for excretion | Polymorphisms affect vitamin K clearance and drug interactions |
| UGT1A6 | Conjugates vitamin K metabolites | Potential role in inter-individual variability in vitamin K catabolism |
| SULT1A1 | Sulfates vitamin K metabolites | Less studied but may contribute to phase II metabolism |
| CYP2C9 | Metabolizes vitamin K and warfarin | Major pharmacogene affecting anticoagulant therapy |
| VKORC1 | Recycles vitamin K epoxide, indirectly affects catabolism | Target of warfarin, influences vitamin K homeostasis |
| GGCX | Gamma-glutamyl carboxylase, uses vitamin K | Defects cause coagulation disorders, impacts vitamin K demand |
| APOE | Lipoprotein involved in vitamin K transport | Affects tissue distribution and catabolism |
| ABCB1 | Transports vitamin K and metabolites | May influence excretion and drug resistance |
| NR1I2 | PXR, regulates expression of CYP and UGT enzymes | Nuclear receptor controlling catabolic gene expression |
| AHR | Aryl hydrocarbon receptor, induces CYP enzymes | Environmental factors may alter vitamin K catabolism |
| NFE2L2 | Nrf2, regulates antioxidant and phase II enzymes | Modulates NQO1 and UGT expression |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates fatty acid oxidation, may affect side chain shortening |
| CYP3A4 | Broad-spectrum oxidase, may oxidize vitamin K | Potential role in vitamin K catabolism in liver |
| EPHX1 | Epoxide hydrolase, processes vitamin K epoxide | Involved in detoxification of epoxides |
| GSTP1 | Glutathione S-transferase, conjugates reactive metabolites | Protects against oxidative stress from quinones |
| NQO2 | Quinone reductase, may reduce vitamin K | Less characterized but potential backup for NQO1 |
How Is vitamin K catabolic process Regulated?
The vitamin K catabolic process is regulated at multiple levels. Transcriptional regulation of key enzymes such as NQO1 and UGTs is controlled by nuclear receptors including Nrf2 (NFE2L2) and PXR (NR1I2), which respond to oxidative stress and xenobiotics. Additionally, the vitamin K cycle, involving VKORC1 and GGCX, indirectly influences catabolism by determining the availability of vitamin K epoxide for breakdown. Post-translational modifications and substrate availability also modulate enzyme activity.
vitamin K catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP4F2 | Warfarin dose variability, coagulation | Knockout mouse, point mutation knock-in |
| VKORC1 | Warfarin resistance, vitamin K deficiency | Knock-in of human variants in mice |
| NQO1 | Cancer susceptibility, oxidative stress | Knockout cell lines, overexpression |
| UGT1A1 | Gilbert syndrome, drug metabolism | Knockout hepatocytes, point mutation |
| GGCX | Vitamin K-dependent coagulation factor deficiency | Knockout zebrafish, knock-in models |
Coagulation Disorders
Impaired vitamin K catabolism can lead to altered vitamin K levels, affecting gamma-carboxylation of clotting factors II, VII, IX, and X. This may result in bleeding disorders or thrombosis. Genetic variants in CYP4F2 and VKORC1 influence warfarin dose requirements and bleeding risk.
Bone Health and Osteoporosis
Vitamin K is essential for carboxylation of osteocalcin, a protein involved in bone mineralization. Dysregulation of vitamin K catabolism may contribute to reduced bone density and increased fracture risk. Studies suggest that vitamin K supplementation may benefit bone health, partly through modulation of catabolic pathways.
Cardiovascular Calcification
Matrix Gla protein (MGP) requires vitamin K-dependent carboxylation to inhibit vascular calcification. Enhanced catabolism of vitamin K could reduce MGP activity, promoting arterial calcification and cardiovascular disease.
Cancer and Oxidative Stress
Quinone metabolites generated during vitamin K catabolism can induce oxidative stress and DNA damage. NQO1 polymorphisms have been associated with cancer susceptibility, highlighting the importance of detoxification pathways.
From vitamin K catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NQO1 deficiency alter vitamin K catabolism? | NQO1 knockout cell line (e.g., HepG2) |
| How do CYP4F2 variants affect vitamin K metabolite profile? | Point mutation knock-in in HepG2 or primary hepatocytes |
| Can overexpression of UGT1A1 enhance vitamin K clearance? | UGT1A1 overexpression lentiviral model |
| What is the tissue-specific role of VKORC1 in catabolism? | Tissue-specific knockout mouse |
| Does Nrf2 regulate UGT and NQO1 expression? | Nrf2 knockout and tagged knock-in reporter |
| Can CRISPR screen identify novel catabolic genes? | Genome-wide CRISPR knockout library in liver cells |
How to Study the vitamin K catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Vitamin K metabolites | Quantification in plasma, liver, urine |
| RNA-seq | Gene expression changes | Identifying regulatory pathways |
| CRISPR knockout | Gene function loss | Determining essential catabolic enzymes |
| CRISPR knock-in | Specific mutations | Modeling human polymorphisms |
| Overexpression | Gain-of-function | Testing enhanced catabolism |
| Enzymatic assay | Catalytic activity | Screening inhibitors/activators |
| Western blot | Protein levels | Validating expression changes |
| Immunohistochemistry | Tissue localization | Mapping enzyme distribution |
Metabolomics and Mass Spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for quantifying vitamin K and its metabolites in biological samples. This method allows researchers to track the catabolic pathway by measuring intermediates such as vitamin K epoxide, hydroxylated forms, and glucuronides.
Transcriptomics and RNA-seq
RNA sequencing can reveal changes in expression of genes involved in vitamin K catabolism under different conditions, such as oxidative stress or drug treatment. This helps identify regulatory networks and potential therapeutic targets.
CRISPR-Cas9 Genome Editing
CRISPR knockout, knock-in, and point mutation models enable precise dissection of gene function in vitamin K catabolism. For example, knocking out NQO1 or UGT1A1 in hepatocytes can reveal their contribution to metabolite clearance.
Enzymatic Assays
In vitro enzymatic assays using recombinant enzymes (e.g., NQO1, UGTs) and vitamin K substrates can measure catalytic activity, kinetics, and inhibition. These assays are useful for screening potential modulators of catabolism.
How CRISPR Can Be Used to Study GO:0042377 vitamin K catabolic process
Knockout
CRISPR knockout of genes such as NQO1, UGT1A1, or CYP4F2 in cell lines (e.g., HepG2, primary hepatocytes) can abolish their catabolic activity, leading to accumulation of vitamin K metabolites. These models help establish causality and identify rate-limiting steps.
Point Mutation
Introducing specific point mutations (e.g., CYP4F2*3, VKORC1 -1639G>A) using CRISPR base editing or homology-directed repair allows researchers to study the impact of human genetic variants on vitamin K catabolism and drug response.
Knock-in
Knock-in of reporter tags (e.g., GFP, FLAG) into endogenous catabolic genes enables real-time tracking of protein expression, localization, and interaction. This is useful for understanding dynamic regulation of the pathway.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of catabolic enzymes can enhance vitamin K breakdown, providing a model to study the effects of accelerated catabolism on coagulation and bone health.
How EDITGENE Supports vitamin K catabolic process Research
Researchers studying vitamin K catabolic process-related genes often need to determine whether a candidate gene is causally involved in vitamin K breakdown, how specific mutations affect enzyme function, and whether modulating its expression alters metabolite profiles. EDITGENE provides end-to-end CRISPR solutions to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for vitamin K catabolic process research.
Frequently Asked Questions About vitamin K catabolic process
What is GO:0042377 vitamin K catabolic process?
GO:0042377 is a Gene Ontology term describing the chemical reactions and pathways that break down vitamin K forms, including phylloquinone and menaquinones, into excretable metabolites.
What genes are involved in vitamin K catabolic process?
Key genes include NQO1, CYP4F2, UGT1A1, UGT1A6, SULT1A1, and VKORC1, among others.
Why is vitamin K catabolism important?
It maintains vitamin K homeostasis, prevents toxicity, and regulates availability of vitamin K for coagulation and bone health.
What diseases are linked to vitamin K catabolic process?
Dysregulation is associated with coagulation disorders, osteoporosis, cardiovascular calcification, and cancer susceptibility.
How is vitamin K catabolism studied?
Methods include LC-MS/MS metabolomics, RNA-seq, enzymatic assays, and CRISPR-based gene editing.
What are the main enzymes in vitamin K catabolism?
Cytochrome P450 enzymes, NQO1, and UDP-glucuronosyltransferases are major players.
Can CRISPR be used to study vitamin K catabolism?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are powerful tools to dissect gene function in this pathway.
Where does vitamin K catabolism occur?
Primarily in the liver, but also in other tissues such as kidney and intestine.
What are the products of vitamin K catabolism?
Water-soluble conjugated metabolites, such as glucuronides and sulfates, which are excreted in bile and urine.
How does vitamin K catabolism affect warfarin therapy?
Genetic variants in CYP4F2 and VKORC1 alter vitamin K catabolism and influence warfarin dose requirements.
Conclusion
GO:0042377 vitamin K catabolic process is a vital biological pathway that ensures proper vitamin K homeostasis and prevents toxicity. Its dysregulation has significant implications for coagulation, bone health, and cardiovascular disease. Advances in CRISPR-based models and metabolomics are accelerating our understanding of the genetic and biochemical mechanisms underlying this process. EDITGENE offers comprehensive services to support research in this field, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Traber MG. 2014. Vitamin K conundrums.. Mol Nutr Food Res 58(8):1589 PMID: 25088827
- 2. Halder M et al.. 2019. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease.. Int J Mol Sci 20(4) PMID: 30791399
- 3. Shearer MJ. 1995. Vitamin K.. Lancet 345(8944):229-34 PMID: 7823718
- 4. Tarento TDC et al.. 2019. A potential biotechnological process for the sustainable production of vitamin K(1).. Crit Rev Biotechnol 39(1):1-19 PMID: 29793354
- 5. Berkner KL. 2008. Vitamin K-dependent carboxylation.. Vitam Horm 78:131-56 PMID: 18374193
- 7. Huysman MW et al.. 1994. The vitamin K controversy.. Curr Opin Pediatr 6(2):129-34 PMID: 8032391
- 8. Stafford DW. 2005. The vitamin K cycle.. J Thromb Haemost 3(8):1873-8 PMID: 16102054
